Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for AMGN, sign up here.
Income Statement
Revenue
$28.2bn
Gross Profit
$19.7bn
Earning before Tax
$7.9bn
Net Income
$6.7bn
Net Income Common Shareholders
$6.7bn
EPS
12.56
Balance Sheet
Cash
$10.9bn
Debt
$64.6bn
Assets
$97.2bn
Liabilities
$90.9bn
Equity
$6.2bn
Enterprise Value
$179.9bn
Cash Flow Statement
Net Cash from Operations
$8.5bn
Net Cash from Investing
$-26.2bn
Net Cash from Financing
$21.0bn
Net Cash Flow
$3.3bn
Free Cash Flow
$7.4bn
Free Cash Flow per Share
$13.76
Metrics
Price to Equity
22.95
Price to Equity (Damodaran)
22.93
Price to Book
24.73
Net Margin
0.24
Return on Equity
1.03
Return on Sales
0.38
Get immediate access to 5-years of reference grade data for AMGN for free.
Sign upAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company''s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet''s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Company Info
Industry
Drug Manufacturers - General
Employees
26,700
Address
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
Phone
805 447 1000
Website
Last Updated
2024-02-16
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.